TY - JOUR
T1 - Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
AU - Benson, Al B.
AU - Venook, Alan P.
AU - Al-Hawary, Mahmoud M.
AU - Arain, Mustafa A.
AU - Chen, Yi Jen
AU - Ciombor, Kristen K.
AU - Cohen, Stacey
AU - Cooper, Harry S.
AU - Deming, Dustin
AU - Farkas, Linda
AU - Garrido-Laguna, Ignacio
AU - Grem, Jean L.
AU - Gunn, Andrew
AU - Hecht, J. Randolph
AU - Hoffe, Sarah
AU - Hubbard, Joleen
AU - Hunt, Steven
AU - Johung, Kimberly L.
AU - Kirilcuk, Natalie
AU - Krishnamurthi, Smitha
AU - Messersmith, Wells A.
AU - Meyerhardt, Jeffrey
AU - Miller, Eric D.
AU - Mulcahy, Mary F.
AU - Nurkin, Steven
AU - Overman, Michael J.
AU - Parikh, Aparna
AU - Patel, Hitendra
AU - Pedersen, Katrina
AU - Saltz, Leonard
AU - Schneider, Charles
AU - Shibata, David
AU - Skibber, John M.
AU - Sofocleous, Constantinos T.
AU - Stoffel, Elena M.
AU - Stotsky-Himelfarb, Eden
AU - Willett, Christopher G.
AU - Gregory, Kristina M.
AU - Gurski, Lisa A.
N1 - Publisher Copyright:
© 2021 Harborside Press. All rights reserved.
PY - 2021
Y1 - 2021
N2 - This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Colon Cancer focuses on systemic therapy options for the treatment of metastatic colorectal cancer (mCRC), because important updates have recently been made to this section. These updates include recommendations for first-line use of checkpoint inhibitors for mCRC, that is deficient mismatch repair/ microsatellite instability-high, recommendations related to the use of biosimilars, and expanded recommendations for biomarker testing. The systemic therapy recommendations now include targeted therapy options for patients with mCRC that is HER2-amplified, or BRAF V600E mutation-positive. Treatment and management of nonmetastatic or resectable/ablatable metastatic disease are discussed in the complete version of the NCCN Guidelines for Colon Cancer available at NCCN.org. Additional topics covered in the complete version include risk assessment, staging, pathology, posttreatment surveillance, and survivorship.
AB - This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Colon Cancer focuses on systemic therapy options for the treatment of metastatic colorectal cancer (mCRC), because important updates have recently been made to this section. These updates include recommendations for first-line use of checkpoint inhibitors for mCRC, that is deficient mismatch repair/ microsatellite instability-high, recommendations related to the use of biosimilars, and expanded recommendations for biomarker testing. The systemic therapy recommendations now include targeted therapy options for patients with mCRC that is HER2-amplified, or BRAF V600E mutation-positive. Treatment and management of nonmetastatic or resectable/ablatable metastatic disease are discussed in the complete version of the NCCN Guidelines for Colon Cancer available at NCCN.org. Additional topics covered in the complete version include risk assessment, staging, pathology, posttreatment surveillance, and survivorship.
KW - Biosimilar Pharmaceuticals
KW - Colonic Neoplasms/diagnosis
KW - DNA Mismatch Repair
KW - Humans
KW - Microsatellite Instability
KW - Mutation
UR - http://www.scopus.com/inward/record.url?scp=85101218872&partnerID=8YFLogxK
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000631864200010&DestLinkType=FullRecord&DestApp=WOS
U2 - 10.6004/jnccn.2021.0012
DO - 10.6004/jnccn.2021.0012
M3 - Article
C2 - 33724754
SN - 1540-1405
VL - 19
SP - 329
EP - 359
JO - Journal of the National Comprehensive Cancer Network : JNCCN
JF - Journal of the National Comprehensive Cancer Network : JNCCN
IS - 3
ER -
